[Chronic myeloid leukemia maintained major molecular response with intermittent dosage of imatinib mesylate].
Authors:
- Kazuho MiyashitaKMKazuho Miyashita
- Katsumichi FujimakiKFKatsumichi Fujimaki
- Yoshiaki IshigatsuboYIYoshiaki Ishigatsubo
- 1 March 2013
- journal article
- case report
- Vol. 40 (3) , 405-7